Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
JGA President Prefers 60% Rule for NHI Generic Prices, Fails to Gain Support on Five Generic Price Ranges
Japan Generic Medicines Association (JGA) President Itsuro Yoshida requested the health ministry to set the NHI prices of first generic versions at 60% of the original drug price, instead of 50%, if the ministry is actually going to introduce a…
To read the full story
Related Article
- CSIMC Continues to Fire Barbs at “Precursor Premium” Despite Industry Appeal
December 10, 2013
- September Price Settlement Rate at 73.5%; Low Figure Blamed on Pharmacy Chains
December 10, 2013
- Mr Umeda of PhRMA Opposes Proposal to Revise Foreign Average Price Adjustment Rule
December 10, 2013
- FPMAJ OKs Concession Plan on Key Premium; Bill Payers Stick to Opposition
December 9, 2013
- Average Drug Price Discrepancy Rate at 8.2%: Health Ministry
December 9, 2013
ORGANIZATION
- Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
- FPMAJ Calls for Greater Support for Stable Drug Supplies in Honebuto Policy
May 22, 2026
- JPMA Exec Urges Broader Debate on Japan’s CEA System
May 22, 2026
- COVID-19 Vaccination Rates Fall as Out-of-Pocket Costs Rise: Jiji Survey
May 21, 2026
- Awareness of HPV Vaccination for Males Stands at 39.4%: Survey
May 21, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…